We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+5.39%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
(-10%)
Cap. Flow
-$49.5M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$57.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$27M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$25.5M |
| 4 |
BridgeBio Pharma
BBIO
|
+$20.9M |
| 5 |
AN2 Therapeutics
ANTX
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$167M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$58.8M |
| 3 |
Morphic Holding, Inc. Common Stock
MORF
|
+$15.2M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$10.2M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$6.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Miscellaneous | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Mirum Pharmaceuticals
MIRM
$5.19B
| $204M | 13.58% |
6,470,392
+2,110,285
| +48% | +$57.8M |
2022 Q1
6 quarters
|
|
2
DELISTED
HilleVax
HLVX
| $132M | 8.74% |
9,781,472
| – | – |
2022 Q2
5 quarters
|
|
3
Krystal Biotech
KRYS
$9.79B
| $115M | 7.62% |
988,460
-1,800
| -0.2% | -$220K |
2022 Q1
6 quarters
|
|
4
NewAmsterdam Pharma
NAMS
$2.39B
| $112M | 7.45% |
12,131,705
+1,259,902
| +12% | +$13.6M |
2022 Q4
3 quarters
|
|
5
Phathom Pharmaceuticals
PHAT
$599M
| $105M | 6.96% |
10,109,279
| – | – |
2022 Q1
6 quarters
|
|
|
6
BridgeBio Pharma
BBIO
$12.7B
| $71.9M | 4.77% |
2,725,949
+737,073
| +37% | +$20.9M |
2023 Q1
2 quarters
|
|
7
Vaxcyte
PCVX
$10.6B
| $59.4M | 3.94% |
1,164,405
| – | – |
2022 Q1
6 quarters
|
|
8
Rhythm Pharmaceuticals
RYTM
$5.97B
| $54.4M | 3.61% |
2,371,304
+204,082
| +9% | +$4.57M |
2022 Q3
4 quarters
|
|
|
VRNA
9
DELISTED
Verona Pharma
VRNA
| $49.1M | 3.26% |
3,014,349
+70,000
| +2% | +$1.35M |
2022 Q3
4 quarters
|
|
10
DELISTED
Crinetics Pharmaceuticals
CRNX
| $47.3M | 3.14% |
1,589,931
+175,108
| +12% | +$3.61M |
2022 Q1
6 quarters
|
|
11
Arcutis Biotherapeutics
ARQT
$3.32B
| $46.1M | 3.06% |
8,684,232
| – | – |
2022 Q1
6 quarters
|
|
12
DELISTED
Alpine Immune Sciences Inc
ALPN
| $34.2M | 2.27% |
2,985,757
| – | – |
2022 Q1
6 quarters
|
|
13
Tarsus Pharmaceuticals
TARS
$3.38B
| $31.8M | 2.11% |
1,787,527
| – | – |
2022 Q1
6 quarters
|
|
14
DELISTED
KalVista Pharmaceuticals
KALV
| $31.2M | 2.07% |
3,238,859
| – | – |
2022 Q1
6 quarters
|
|
15
Disc Medicine
IRON
$2.14B
| $30.8M | 2.04% |
655,000
| – | – |
2023 Q2
1 quarter
|
|
|
16
Rocket Pharmaceuticals
RCKT
$243M
| $28.7M | 1.91% |
+1,403,013
| New | +$25.5M |
2023 Q3
0 quarters
|
|
17
Revolution Medicines
RVMD
$41.5B
| $27.6M | 1.83% |
997,455
+142,971
| +17% | +$4.24M |
2023 Q1
2 quarters
|
|
|
18
DELISTED
Apellis Pharmaceuticals
APLS
| $23.4M | 1.55% |
+614,043
| New | +$27M |
2023 Q3
0 quarters
|
|
|
19
AN2 Therapeutics
ANTX
$134M
| $22.3M | 1.48% |
+1,388,889
| New | +$15.7M |
2023 Q3
0 quarters
|
|
20
DELISTED
Merus
MRUS
| $17.6M | 1.17% |
746,479
| – | – |
2022 Q1
6 quarters
|
|
21
Jade Biosciences
JBIO
$855M
| $16.4M | 1.09% |
34,425
+6,000
| +21% | +$3.25M |
2023 Q1
2 quarters
|
|
22
AnaptysBio
ANAB
$1.4B
| $16.2M | 1.07% |
899,700
| – | – |
2022 Q1
6 quarters
|
|
23
Savara
SVRA
$978M
| $15.1M | 1% |
+4,000,000
| New | +$14.3M |
2023 Q3
0 quarters
|
|
24
Trevi Therapeutics
TRVI
$1.72B
| $15M | 1% |
6,881,090
| – | – |
2022 Q2
5 quarters
|
|
25
Cogent Biosciences
COGT
$4.88B
| $14.6M | 0.97% |
1,501,383
| – | – |
2022 Q1
6 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2023 Portfolio in Review
As of Q3 2023, Frazier Life Sciences Management held 56 positions worth $1.51B, down 10% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Frazier Life Sciences Management withdrew a net $49.5M in Q3 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $167M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Life Sciences Management opened a new position in Apellis Pharmaceuticals worth $23.4M.
- Frazier Life Sciences Management's largest Q3 2023 buy was Apellis Pharmaceuticals: 614,043 shares worth $23.4M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q3 2023, an estimated $57.8M increase.
- Frazier Life Sciences Management's biggest Q3 2023 reduction was Syndax Pharmaceuticals, cutting an estimated $58.8M.
- Frazier Life Sciences Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $167M.
- Frazier Life Sciences Management's ten largest holdings make up 63% of its $1.51B portfolio in Q3 2023.
- Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2023.
- Frazier Life Sciences Management's portfolio value fell 10% quarter-over-quarter to $1.51B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.